Carboplatin and docetaxel in advanced non-small-cell lung cancer: Results of a multicenter phase II study

Sakkaraiappan Ramalingam, Tracy W. Dobbs, Avi I. Einzig, Slawomir Wojtowicz-Praga, Marianne Cascino, Phillip Bonomi, Chandra P. Belani

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Background: To evaluate the efficacy of carboplatin and docetaxel combination in patients with advanced non-small-cell lung cancer. Methods: In a phase II study, patients with inoperable stage IIIB or stage IV non-small-cell lung cancer (ECOG performance status of 0 or 1) were treated with the combination of carboplatin AUC 5 mg/ml·min and docetaxel 80 mg/m 2 administered once every 3 weeks. Results: A total of 45 patients were accrued to the study. The median age was 62 years and adenocarcinoma was the most common histology. Patients received a median of four cycles of chemotherapy. The objective response rate was 29% with a median survival of 11.9 months among evaluable patients. The 1-year survival rate was 47%. Febrile neutropenia (17%) was the most common hematological toxicity associated with the regimen whereas grade 3 fatigue (4%) was the major nonhematological toxicity. Conclusions: The combination of carboplatin plus docetaxel is well tolerated and is effective for the treatment of patients with previously untreated advanced or metastatic non-small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)439-444
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Issue number5
StatePublished - May 2004

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Carboplatin and docetaxel in advanced non-small-cell lung cancer: Results of a multicenter phase II study'. Together they form a unique fingerprint.

Cite this